Patents by Inventor David Enot
David Enot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11313866Abstract: A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.Type: GrantFiled: September 11, 2017Date of Patent: April 26, 2022Assignee: InfanDx AGInventors: Matthias Keller, Hans-Peter Deigner, David Enot, Matthias Kohl, Ronnaug Solberg, Olga Saugstad, Therese Koal
-
Patent number: 10514383Abstract: Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.Type: GrantFiled: October 25, 2012Date of Patent: December 24, 2019Assignee: InfanDx AGInventors: Matthias Keller, David Enot
-
Publication number: 20190331682Abstract: The present invention relates to a method of predicting assessing or monitoring the sensitivity of a subject having a cancer to an immunotherapy, and to corresponding kits. The method of predicting, assessing or monitoring the sensitivity of a subject having a tumor to an immunotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one biomarker, for example at least two biomarkers, and when the expression level is determined a step b) of comparing said expression level to reference expression level(s) or to reference expression ratio(s), thereby predicting, assessing or monitoring whether the subject having a tumor is responsive or resistant to the proposed immunotherapy.Type: ApplicationFiled: February 17, 2017Publication date: October 31, 2019Inventors: LAURENCE ZITVOGEL, NICOLAS JACQUELOT, DAVID ENOT, SYLVIE SEIJO-RUSAKIEWICZ
-
Publication number: 20180011111Abstract: A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.Type: ApplicationFiled: September 11, 2017Publication date: January 11, 2018Applicant: InfanDx AGInventors: Matthias Keller, Hans-Peter Deigner, David Enot, Matthias Kohl, Ronnaug Solberg, Olga Saugstad, Therese Koal
-
Patent number: 9791459Abstract: A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.Type: GrantFiled: May 4, 2010Date of Patent: October 17, 2017Assignee: InfanDx AGInventors: Matthias Keller, Hans-Peter Deigner, David Enot, Matthias Kohl, Ronnaug Solberg, Ola Didrik Saugstad, Therese Koal
-
Publication number: 20140308687Abstract: Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.Type: ApplicationFiled: October 25, 2012Publication date: October 16, 2014Applicant: InfanDx AGInventors: Matthias Keller, David Enot
-
Method and Use of Metabolites for the Diagnosis of Inflammatory Brain Injury in Preterm Born Infants
Publication number: 20140297195Abstract: The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.Type: ApplicationFiled: February 22, 2012Publication date: October 2, 2014Applicant: InfanDx AGInventors: Matthias Keller, Carina Mallard, Hans-Peter Deigner, David Enot, Emeka I. Igwe -
Publication number: 20120326025Abstract: The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7?-Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5?,6?-Epoxycholesterol (5b,6b,EPC); 5g302,6g302-Epoxycholesterol (5a,6a,EPC); and 4?-Hydroxycholesterol (4BOHC); for prognosticating relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.Type: ApplicationFiled: January 28, 2011Publication date: December 27, 2012Applicant: IMG Institut fur Medizinische Genomforschung Planu ngsgesellschaftInventors: Klaus Weinberger, Hans-Peter Deigner, Emeka Ignatius Igwe, David Enot, Guido Dallmann, Helmut Klocker
-
Publication number: 20120208282Abstract: The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.Type: ApplicationFiled: June 23, 2010Publication date: August 16, 2012Inventors: Hans-Peter Deigner, Matthias Kohl, Matthias Keller, Therese Koal, David Enot
-
Publication number: 20120202240Abstract: The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method.Type: ApplicationFiled: July 23, 2010Publication date: August 9, 2012Inventors: Hans-Peter Deigner, Matthias Kohl, David Enot, Theresa Koal, Matthias Keller
-
Publication number: 20120136581Abstract: A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.Type: ApplicationFiled: May 4, 2010Publication date: May 31, 2012Inventors: Matthias Keller, Hans-Peter Deigner, David Enot, Matthias Kohl, Ronnaug Solberg, Olga Didrik Saugstad, Therese Koal